{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:52:40Z","timestamp":1781650360550,"version":"3.54.5"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["AbbVie"],"award-info":[{"award-number":["AbbVie"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Parkinson\u2019s disease (PD) is characterized by motor and non-motor symptoms that fluctuate as oral medication wears off, causing periods when symptoms return (\u201cOFF\u201d time) and periods of control (\u201cON\u201d time). These fluctuations often occur at night and early morning. Sleep disturbance (SD) and early-morning OFF time (EMO) have been shown to decrease health-related quality of life (HRQoL) in people with PD (PwP). However, limited evidence exists on how these symptoms impact health state utility values (HSUVs) used in economic modeling. This study aimed to estimate the burden and disutility of SD and EMO in PwP through vignettes valued using the EQ-5D-5\u00a0L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methodology<\/jats:title>\n                    <jats:p>An online survey was completed by adults (\u2265\u200930 years) with self-reported PD diagnosis for \u2265\u20095 years and \u2265\u20092\u00a0h\/day of OFF time, on oral PD medications, and residing in the US or UK. The survey included EQ-5D-5\u00a0L and EQ-VAS assessments for 4 vignettes\u2014No SD or EMO, SD (without EMO), EMO (without SD), and Both SD and EMO\u2014plus questions exploring the burden of SD and EMO. EQ-5D-5\u00a0L responses were converted into US utility values to estimate HSUVs and the disutility of SD and EMO.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-five individuals completed the survey; 52.00% were male, and 78.66% resided in the US. The average age was 64.32 years, with a mean time since diagnosis of 9.82 years and an average OFF time of 3.91\u00a0h\/day. In the previous week, 96.00% and 98.67% of respondents reported experiencing SD and EMO, respectively. The presence of either SD (HSUV: 0.796) or EMO (HSUV: 0.701) alone resulted in lower EQ-5D-5\u00a0L utilities, with the presence of both valued least (HSUV: 0.528), compared with when both SD and EMO were absent (HSUV: 0.911). EQ-VAS scores ranged from 81.01 for no symptoms to 48.41 for both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SD and EMO impose a significant burden on PwP and decrease HSUVs. As SD and EMO were associated with significant disutility, they should be incorporated into economic models to comprehensively assess PD treatment benefits. Raising awareness among PwP and healthcare providers and prioritizing treatments that minimize SD and EMO can reduce their burden and improve HRQoL for PwP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s41687-026-01053-w","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:49:05Z","timestamp":1776160145000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden and disutility of sleep disturbance and early morning OFF symptoms in people with advancing Parkinson\u2019s disease: a vignette-based approach using the EQ-5D-5L"],"prefix":"10.1186","volume":"10","author":[{"given":"Josefa","family":"Domingos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Malaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pahwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Ray","family":"Chaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Boeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Kuharic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjana","family":"Lalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie H.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Heisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Mohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Penton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"9","key":"1053_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.nrl.2014.10.010","volume":"31","author":"K Berganzo","year":"2016","unstructured":"Berganzo K, Tijero B, Gonz\u00e1lez-Eizaguirre A, Somme J, Lezcano E, Gabilondo I et al (2016) Motor and non-motor symptoms of Parkinson\u2019s disease and their impact on quality of life and on different clinical subgroups. Neurolog\u00eda (English Edition) 31(9):585\u2013591 https:\/\/doi.org\/10.1016\/j.nrl.2014.10.010","journal-title":"Neurolog\u00eda (English Edition)"},{"key":"1053_CR2","unstructured":"Liang T-W, Tarsy D. Medical management of motor fluctuations and dyskinesia in Parkinson disease. UpToDate, Waltham MA: UpToDate Inc, Available: https:\/\/www.uptodate.com\/contents\/medical-management-of-motor-fluctuations-and-dyskinesia-in-parkinson-disease. H.1"},{"issue":"4","key":"1053_CR3","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","volume":"80","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Silverberg JI, Nemoto O, Forman SB, Wilke A, Prescilla R et al (2019) Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study. J Am Acad Dermatol 80(4):913\u2013921 e9. https:\/\/doi.org\/10.1016\/j.jaad.2018.01.018","journal-title":"J Am Acad Dermatol"},{"key":"1053_CR4","doi-asserted-by":"publisher","unstructured":"Kataoka H, Sugie K (2024) Early-morning OFF in Parkinson\u2019s disease: a systematic literature review and current therapeutics. Clin Neurol Neurosurg. 108493 https:\/\/doi.org\/10.1016\/j.clineuro.2024.108493","DOI":"10.1016\/j.clineuro.2024.108493"},{"issue":"5","key":"1053_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1111\/ene.13895","volume":"26","author":"F Stocchi","year":"2019","unstructured":"Stocchi F, Coletti C, Bonassi S, Radicati F, Vacca L (2019) Early-morning OFF and levodopa dose failures in patients with Parkinson\u2019s disease attending a routine clinical appointment using Time\u2010to\u2010ON Questionnaire. Eur J Neurol 26(5):821\u2013826 https:\/\/doi.org\/10.1111\/ene.13895","journal-title":"Eur J Neurol"},{"issue":"1","key":"1053_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.14802\/jmd.24227","volume":"18","author":"I Boura","year":"2025","unstructured":"BouraI, Poplawska-Domaszewicz K, Spanaki C, Chen R, Urso D, van Coller R et al (2025) Non-Motor Fluctuations in Parkinson\u2019s Disease: Underdiagnosed Yet Important. J Mov Disorders 18(1):1\u201316 https:\/\/doi.org\/10.14802\/jmd.24227","journal-title":"J Mov Disorders"},{"key":"1053_CR7","doi-asserted-by":"publisher","first-page":"681773","DOI":"10.3389\/fnagi.2021.681773","volume":"13","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang ZE, Shi D, Zhao Y, Huang L, Zhao Y et al (2021) Nocturnal Sleep Problems Mediate the Impact on Quality of Life of Early Morning Off in Parkinson\u2019s Disease. Front Aging Neurosci 13:681773. https:\/\/doi.org\/10.3389\/fnagi.2021.681773","journal-title":"Front Aging Neurosci"},{"key":"1053_CR8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.sleep.2021.02.036","volume":"81","author":"C Liguori","year":"2021","unstructured":"Liguori C, De Franco V, Cerroni R, Spanetta M, Mercuri NB, Stefani A et al (2021) Sleep problems affect quality of life in Parkinson\u2019s disease along disease progression. Sleep Med 81:307\u2013311. https:\/\/doi.org\/10.1016\/j.sleep.2021.02.036","journal-title":"Sleep Med"},{"key":"1053_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2016.02.066","volume":"364","author":"R Onozawa","year":"2016","unstructured":"Onozawa R, Tsugawa J, Tsuboi Y, Fukae J, Mishima T, Fujioka S (2016) The impact of early morning off in Parkinson\u2019s disease on patient quality of life and caregiver burden. J Neurol Sci 364:1\u20135. https:\/\/doi.org\/10.1016\/j.jns.2016.02.066","journal-title":"J Neurol Sci"},{"issue":"11","key":"1053_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.parkreldis.2014.09.013","volume":"20","author":"A Rizos","year":"2014","unstructured":"Rizos A, Martinez-Martin P, Odin P, Antonini A, Kessel B, Kozul TK et al (2014) Characterizing motor and non-motor aspects of early-morning off periods in Parkinson\u2019s disease: an international multicenter study. Parkinsonism Relat Disord 20(11):1231\u20131235. https:\/\/doi.org\/10.1016\/j.parkreldis.2014.09.013","journal-title":"Parkinsonism Relat Disord"},{"key":"1053_CR11","doi-asserted-by":"publisher","unstructured":"Suzuki K, Miyamoto T, Miyamoto M, Numao A, Sakuta H, Fujita H et al (2014) Sleep disturbances in patients with Parkinson\u2019s disease. In: A Synopsis of Parkinson\u2019s Disease. https:\/\/doi.org\/10.5772\/57320","DOI":"10.5772\/57320"},{"issue":"1","key":"1053_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40035-020-00208-z","volume":"9","author":"C Han","year":"2020","unstructured":"Han C, Mao W, An J, Jiao L, Chan P, China Early Morning Off Study G (2020) Early morning off in patients with Parkinson\u2019s disease: a Chinese nationwide study and a 7-question screening scale. Transl Neurodegener 9(1):29. https:\/\/doi.org\/10.1186\/s40035-020-00208-z","journal-title":"Transl Neurodegener"},{"issue":"6","key":"1053_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/mds.20383","volume":"20","author":"M Stacy","year":"2005","unstructured":"Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP et al (2005) Identification of motor and nonmotor wearing-off in Parkinson\u2019s disease: comparison of a patient questionnaire versus a clinician assessment. Mov disorders: official J Mov Disorder Soc 20(6):726\u2013733 https:\/\/doi.org\/10.1002\/mds.20383","journal-title":"Mov disorders: official J Mov Disorder Soc"},{"issue":"2","key":"1053_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.parkreldis.2013.10.027","volume":"20","author":"F Stocchi","year":"2014","unstructured":"Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M et al (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20(2):204\u2013211 https:\/\/doi.org\/10.1016\/j.parkreldis.2013.10.027","journal-title":"Parkinsonism Relat Disord"},{"issue":"8","key":"1053_CR15","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1002\/mds.25364","volume":"28","author":"C Warren Olanow","year":"2013","unstructured":"Warren Olanow C, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M et al (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing\u2010off in Parkinson\u2019s disease. Mov Disord 28(8):1064\u20131071 https:\/\/doi.org\/10.1002\/mds.25364","journal-title":"Mov Disord"},{"key":"1053_CR16","doi-asserted-by":"publisher","first-page":"106971","DOI":"10.1016\/j.parkreldis.2024.106971","volume":"123","author":"RA Hauser","year":"2024","unstructured":"Hauser RA, Videnovic A, Soares-da-Silva P, Liang GS, Olson K, Jen E et al (2024) OFF-times before, during, and after nighttime sleep periods in Parkinson\u2019s disease patients with motor fluctuations and the effects of opicapone: A post hoc analysis of diary data from BIPARK-1 and-2. Parkinsonism Relat Disord 123:106971 https:\/\/doi.org\/10.1016\/j.parkreldis.2024.106971","journal-title":"Parkinsonism Relat Disord"},{"issue":"1","key":"1053_CR17","doi-asserted-by":"publisher","first-page":"zsz203","DOI":"10.1093\/sleep\/zsz203","volume":"43","author":"H Kataoka","year":"2020","unstructured":"Kataoka H, Saeki K, Yamagami Y, Sugie K, Obayashi K (2020) Quantitative associations between objective sleep measures and early-morning mobility in Parkinson\u2019s disease: cross-sectional analysis of the PHASE study. Sleep 43(1):zsz203 https:\/\/doi.org\/10.1093\/sleep\/zsz203","journal-title":"Sleep"},{"issue":"12","key":"1053_CR18","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/S1474-4422(22)00400-8","volume":"21","author":"MJ Soileau","year":"2022","unstructured":"Soileau MJ, Aldred J, Budur K, Fisseha N, Fung VS, Jeong A et al (2022) Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson\u2019s disease: a randomised, double-blind, active-controlled, phase 3 trial. Lancet Neurol 21(12):1099\u20131109 https:\/\/doi.org\/10.1016\/S1474-4422(22)00400-8","journal-title":"Lancet Neurol"},{"issue":"6","key":"1053_CR19","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1007\/s40120-023-00533-1","volume":"12","author":"J Aldred","year":"2023","unstructured":"Aldred J, Freire-Alvarez E, Amelin AV, Antonini A, Bergmans B, Bergquist F et al (2023) Continuous subcutaneous foslevodopa\/foscarbidopa in Parkinson\u2019s disease: Safety and efficacy results from a 12-month, single-arm, open-label, phase 3 study. Neurol Therapy 12(6):1937\u20131958 https:\/\/doi.org\/10.1007\/s40120-023-00533-1","journal-title":"Neurol Therapy"},{"key":"1053_CR20","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.parkreldis.2020.12.024","volume":"83","author":"R Katzenschlager","year":"2021","unstructured":"Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR et al (2021) Long-term safety and efficacy of apomorphine infusion in Parkinson\u2019s disease patients with persistent motor fluctuations: results of the open-label phase of the TOLEDO study. Parkinsonism Relat Disord 83:79\u201385 https:\/\/doi.org\/10.1016\/j.parkreldis.2020.12.024","journal-title":"Parkinsonism Relat Disord"},{"issue":"4","key":"1053_CR21","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40120-024-00635-4","volume":"13","author":"K Poplawska-Domaszewicz","year":"2024","unstructured":"Poplawska-Domaszewicz K, Batzu L, Falup-Pecurariu C, Chaudhuri KR (2024) Subcutaneous Levodopa: A New Engine for the Vintage Molecule. Neurol Therapy 13(4):1055\u20131068 https:\/\/doi.org\/10.1007\/s40120-024-00635-4","journal-title":"Neurol Therapy"},{"issue":"7","key":"1053_CR22","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3233\/JPD-223295","volume":"12","author":"KR Chaudhuri","year":"2022","unstructured":"Chaudhuri KR, Antonini A, Pahwa R, Odin P, Titova N, Thakkar S et al (2022) Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-month follow-up. J Parkinson\u2019s Disease 12(7):2071\u20132083 https:\/\/doi.org\/10.3233\/JPD-223295","journal-title":"J Parkinson\u2019s Disease"},{"issue":"5","key":"1053_CR23","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1007\/s00415-023-11615-3","volume":"270","author":"A Fasano","year":"2023","unstructured":"Fasano A, Garc\u00eda-Ramos R, Gurevich T, Jech R, Bergmann L, Sanchez-Soli\u00f1o O et al (2023) Levodopa\u2013carbidopa intestinal gel in advanced Parkinson\u2019s disease: long-term results from COSMOS. J Neurol 270(5):2765\u20132775 https:\/\/doi.org\/10.1007\/s00415-023-11615-3","journal-title":"J Neurol"},{"key":"1053_CR24","doi-asserted-by":"publisher","first-page":"1105650","DOI":"10.3389\/fneur.2023.1105650","volume":"14","author":"\u015e Diaconu","year":"2023","unstructured":"Diaconu \u015e, Irincu L, \u0162\u00een\u0163 D, Falup-Pecurariu C (2023) Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson\u2019s disease. Front Neurol 14:1105650 https:\/\/doi.org\/10.3389\/fneur.2023.1105650","journal-title":"Front Neurol"},{"issue":"2","key":"1053_CR25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3233\/JPD-191862","volume":"10","author":"JRP Zuzu\u00e1rregui","year":"2020","unstructured":"Zuzu\u00e1rregui JRP, Ostrem JL (2020) The impact of deep brain stimulation on sleep in Parkinson\u2019s disease: an update. J Parkinson\u2019s disease 10(2):393\u2013404 https:\/\/doi.org\/10.3233\/JPD-191862","journal-title":"J Parkinson\u2019s disease"},{"issue":"1","key":"1053_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41531-020-00131-0","volume":"6","author":"S Bjerknes","year":"2020","unstructured":"Bjerknes S, Skogseid IM, Hauge TJ, Dietrichs E, Toft M (2020) Subthalamic deep brain stimulation improves sleep and excessive sweating in Parkinson\u2019s disease. NPJ Parkinson\u2019s Disease 6(1):29 https:\/\/doi.org\/10.1038\/s41531-020-00131-0","journal-title":"NPJ Parkinson\u2019s Disease"},{"issue":"2","key":"1053_CR27","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/mds.10639","volume":"19","author":"N Hjort","year":"2004","unstructured":"Hjort N, \u00d8stergaard K, Dupont E (2004) Improvement of sleep quality in patients with advanced Parkinson\u2019s disease treated with deep brain stimulation of the subthalamic nucleus. Mov Disord 19(2):196\u2013199 https:\/\/doi.org\/10.1002\/mds.10639","journal-title":"Mov Disord"},{"issue":"2","key":"1053_CR28","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/mdc3.12375","volume":"4","author":"AW Amara","year":"2017","unstructured":"Amara AW, Walker HC, Joop A, Cutter G, DeWolfe JL, Harding SM et al (2017) Effects of subthalamic nucleus deep brain stimulation on objective sleep outcomes in Parkinson\u2019s disease. Mov disorders Clin Pract 4(2):183\u2013190 https:\/\/doi.org\/10.1002\/mdc3.12375","journal-title":"Mov disorders Clin Pract"},{"key":"1053_CR29","unstructured":"National Institute for Health and Care Excellence (2022) NICE health technology evaluations: the manual"},{"key":"1053_CR30","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 (2020) Choices in methods for economic evaluation\u2014HAS. Methodological Guidance 2020 https:\/\/www.has-sante.fr\/jcms\/r_1499251\/en\/choices-in-methods-for-economic-evaluation"},{"key":"1053_CR31","unstructured":"Zorginstituut Nederland (2016) Guideline for economic evaluations in healthcare. ZIN, Diemen"},{"key":"1053_CR32","unstructured":"EuroQoL EQ-5D-3L. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-3l-about\/. Accessed 13\/09\/2023"},{"key":"1053_CR33","unstructured":"EuroQoL EQ-5D-5L. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed 13\/09\/2023"},{"key":"1053_CR34","unstructured":"Institute for Clinical Economic Review (2020) ICER\u2019s reference case for economic evaluations: principles and rationale. Institute for Clinical and Economic Review Boston, MA, USA"},{"issue":"4","key":"1053_CR35","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s11136-013-0569-4","volume":"23","author":"M\u00c1 Garc\u00eda-Gordillo","year":"2014","unstructured":"Garc\u00eda-Gordillo M\u00c1, del Pozo-Cruz B, Adsuar JC, S\u00e1nchez-Mart\u00ednez FI, Abell\u00e1n-Perpi\u00f1\u00e1n JM (2014) Validation and comparison of 15-D and EQ-5D-5L instruments in a Spanish Parkinson\u2019s disease population sample. Qual Life Res 23(4):1315\u20131326 https:\/\/doi.org\/10.1007\/s11136-013-0569-4","journal-title":"Qual Life Res"},{"issue":"1\u20132","key":"1053_CR36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jns.2015.08.010","volume":"358","author":"A Alvarado-Bola\u00f1os","year":"2015","unstructured":"Alvarado-Bola\u00f1os A, Cervantes-Arriaga A, Rodr\u00edguez-Violante M, Llorens-Arenas R, Calder\u00f3n-Fajardo H, Mill\u00e1n-Cepeda R et al (2015) Convergent validation of EQ-5D-5L in patients with Parkinson\u2019s disease. J Neurol Sci 358(1\u20132):53\u201357 https:\/\/doi.org\/10.1016\/j.jns.2015.08.010","journal-title":"J Neurol Sci"},{"key":"1053_CR37","doi-asserted-by":"crossref","unstructured":"Luo N, Low S, Lau P-N, Au W-L, Tan L (2009) Is EQ-5D a valid quality of life instrument in patients with Parkinson\u2019s disease? A study in Singapore. Ann Acad Med Singap 38(6):521-528","DOI":"10.47102\/annals-acadmedsg.V38N6p521"},{"issue":"1","key":"1053_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1136\/jnnp.69.1.67","volume":"69","author":"A Schrag","year":"2000","unstructured":"Schrag A, Selai C, Jahanshahi M, Quinn NP (2000) The EQ-5D\u2014a generic quality of life measure\u2014is a useful instrument to measure quality of life in patients with Parkinson\u2019s disease. J Neurol Neurosurg Psychiatry 69(1):67\u201373 https:\/\/doi.org\/10.1136\/jnnp.69.1.67","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"9","key":"1053_CR39","doi-asserted-by":"publisher","first-page":"A448","DOI":"10.1016\/j.jval.2017.08.284","volume":"20","author":"R Beale","year":"2017","unstructured":"Beale R, Wickstead R, Chen G, Walker E, Griffiths M (2017) No EQ-5D? Analysis of Alternative Utility Value Sources Used in Nice Appraisals for Oncology Indications. Value Health 20(9):A448","journal-title":"Value Health"},{"issue":"1","key":"1053_CR40","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jval.2010.10.015","volume":"14","author":"JC Tosh","year":"2011","unstructured":"Tosh JC, Longworth LJ, George E (2011) Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals. Value Health 14(1):102\u2013109. https:\/\/doi.org\/10.1016\/j.jval.2010.10.015","journal-title":"Value Health"},{"key":"1053_CR41","unstructured":"Brazier J, Rowen D (2017) NICE DSU technical support document 11: alternatives to EQ-5D for generating health state utility values"},{"issue":"6","key":"1053_CR42","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.jval.2020.12.017","volume":"24","author":"LS Matza","year":"2021","unstructured":"Matza LS, Stewart KD, Lloyd AJ, Rowen D, Brazier JE (2021) Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. Value Health 24(6):812\u2013821. https:\/\/doi.org\/10.1016\/j.jval.2020.12.017","journal-title":"Value Health"},{"issue":"1","key":"1053_CR43","doi-asserted-by":"publisher","first-page":"7537924","DOI":"10.1155\/2020\/7537924","volume":"2020","author":"D Santos-Garc\u00eda","year":"2020","unstructured":"Santos-Garc\u00eda D, de Deus Fonticoba T, Su\u00e1rez Castro E, Aneiros Diaz A, McAfee D (2020) 5-2\u20101 Criteria: A Simple Screening Tool for Identifying Advanced PD Patients Who Need an Optimization of Parkinson\u2019s Treatment. Parkinson\u2019s Disease 2020(1):7537924 https:\/\/doi.org\/10.1155\/2020\/7537924","journal-title":"Parkinson\u2019s Disease"},{"key":"1053_CR44","doi-asserted-by":"crossref","unstructured":"Domingos J, Pahwa R, Antonini A, Malaty IA, De Renzis F, Arija P et al (2025) Preferences for advanced Parkinson\u2019s disease treatments from people with Parkinson\u2019s and care partners: insights from a discrete-choice experiment. Presented at: Am Acad Neurol 5\u2013023","DOI":"10.1212\/WNL.0000000000209041"},{"key":"1053_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12877-016-0207-4","volume":"16","author":"M Oremus","year":"2016","unstructured":"Oremus M, Xie F, Pullenayegum E, Gaebel K (2016) Can the general public use vignettes to discriminate between Alzheimer\u2019s disease health states? BMC Geriatr 16:1\u20137 https:\/\/doi.org\/10.1186\/s12877-016-0207-4","journal-title":"BMC Geriatr"},{"issue":"5","key":"1053_CR46","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.1016\/j.jval.2011.05.007","volume":"14","author":"J Galante","year":"2011","unstructured":"Galante J, Augustovski F, Colantonio L, Bardach A, Caporale J, Marti SG et al (2011) Estimation and comparison of EQ-5D health states\u2019 utility weights for pneumoccocal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health 14(5):S60\u2013S4","journal-title":"Value Health"},{"issue":"6","key":"1053_CR47","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1016\/j.jval.2024.03.2094","volume":"27","author":"A Kim","year":"2024","unstructured":"Kim A, Lee Y, Lee H (2024) PCR216 Exploring Quality of Life in Spinal Muscular Atrophy Patients through Vignette-Based EQ-5D-5L Measurements. Value Health 27(6):S336","journal-title":"Value Health"},{"key":"1053_CR48","unstructured":"Domingos J, Pahwa R, Antonini A, Malaty IA, Lindvall S, De Renzis F et al (2023) Drivers of treatment decisions in advanced Parkinson\u2019s disease: a qualitative study among people with Parkinson\u2019s and caregivers World Parkinson\u2019s Congress (WPC) 2023"},{"issue":"4","key":"1053_CR49","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1002\/mds.23476","volume":"26","author":"C Trenkwalder","year":"2011","unstructured":"Trenkwalder C, Kohnen R, H\u00f6gl B, Metta V, Sixel-D\u00f6ring F, Frauscher B et al (2011) Parkinson\u2019s disease sleep scale\u2014validation of the revised version PDSS\u20102. Mov Disord 26(4):644\u2013652","journal-title":"Mov Disord"},{"issue":"3","key":"1053_CR50","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/hec.3846","volume":"28","author":"MF Jonker","year":"2019","unstructured":"Jonker MF, Donkers B, de Bekker-Grob E, Stolk EA (2019) Attribute level overlap (and color coding) can reduce task complexity, improve choice consistency, and decrease the dropout rate in discrete choice experiments. Health Econ 28(3):350\u2013363. https:\/\/doi.org\/10.1002\/hec.3846","journal-title":"Health Econ"},{"key":"1053_CR51","unstructured":"EuroQoL (2021) EQ-5D-5L. https:\/\/euroqol.org\/eq-5d-instruments\/eq-5d-5l-about\/. Accessed 13\/09\/2023 2023"},{"key":"1053_CR52","unstructured":"Sauer C, Auspurg K, Hinz T (2020) Designing multi-factorial survey experiments: effects of presentation style (text or table), answering scales, and vignette order. Methods, data, analyses: a journal for quantitative methods and survey methodology (mda). 14(2):195\u2013214"},{"issue":"3","key":"1053_CR53","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1177\/0049124115591016","volume":"46","author":"K Auspurg","year":"2017","unstructured":"Auspurg K, J\u00e4ckle A (2017) First equals most important? Order effects in vignette-based measurement. Sociol Methods Res 46(3):490\u2013539","journal-title":"Sociol Methods Res"},{"key":"1053_CR54","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.sleep.2016.06.026","volume":"24","author":"ML Muntean","year":"2016","unstructured":"Muntean ML, Benes H, Sixel-Doring F, Chaudhuri KR, Suzuki K, Hirata K et al (2016) Clinically relevant cut-off values for the Parkinson\u2019s Disease Sleep Scale-2 (PDSS-2): a validation study. Sleep Med 24:87\u201392. https:\/\/doi.org\/10.1016\/j.sleep.2016.06.026","journal-title":"Sleep Med"},{"key":"1053_CR55","unstructured":"RStudio RT (2020) Integrated development environment for R. RStudio, PBC: Boston, MA, USA"},{"key":"1053_CR56","unstructured":"Core RT (2019) R: A language and environment for statistical computing."},{"issue":"8","key":"1053_CR57","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.jval.2019.02.009","volume":"22","author":"AS Pickard","year":"2019","unstructured":"Pickard AS, Law EH, Jiang R, Pullenayegum E, Shaw JW, Xie F et al (2019) United States Valuation of EQ-5D-5L Health States Using an International Protocol. Value Health 22(8):931\u2013941. https:\/\/doi.org\/10.1016\/j.jval.2019.02.009","journal-title":"Value Health"},{"issue":"8","key":"1053_CR58","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/j.1524-4733.2010.00781.x","volume":"13","author":"A Bobinac","year":"2010","unstructured":"Bobinac A, Van Exel N, Rutten FF, Brouwer WB (2010) Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health 13(8):1046\u20131055 https:\/\/doi.org\/10.1111\/j.1524-4733.2010.00781.x","journal-title":"Value Health"},{"issue":"2","key":"1053_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A (2023) Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. PharmacoEconomics 41(2):199\u2013207 https:\/\/doi.org\/10.1007\/s40273-022-01218-7","journal-title":"PharmacoEconomics"},{"issue":"10","key":"1053_CR60","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.3390\/s24103045","volume":"24","author":"K Poplawska-Domaszewicz","year":"2024","unstructured":"Poplawska-Domaszewicz K, Limbachiya N, Lau YH, Chaudhuri KR (2024) Parkinson\u2019s Kinetigraph for wearable sensor detection of clinically unrecognized early-morning Akinesia in Parkinson\u2019s disease: a case report-based observation. Sensors 24(10):3045 https:\/\/doi.org\/10.3390\/s24103045","journal-title":"Sensors"},{"key":"1053_CR61","unstructured":"NICE (2023) Foslevodopa\u2013foscarbidopa for treating advanced Parkinson\u2019s with motor symptoms - Technology appraisal guidance"},{"key":"1053_CR62","unstructured":"NICE (2023) NICE recommended treatment for Parkinson\u2019s set to benefit hundreds - News articles"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-026-01053-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01053-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-026-01053-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:00:37Z","timestamp":1781647237000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s41687-026-01053-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1053"],"URL":"https:\/\/doi.org\/10.1186\/s41687-026-01053-w","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Centralized ethics approval was obtained from Salus IRB on 4 January 2024 with approval number 21091.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AL, ZB, and CHY are employees of AbbVie. PA, MB, DM, and HP are employees of OPEN Health. All authors declare no other competing interests. JD, IM, RP, and KRC have received honoraria as a consultant and\/or advisory board member for AbbVie. MK is a former employee of AbbVie. MH is a former employee of OPEN Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"85"}}